Call for Submissions: AJRCCM ATS 2019 Conference Issue
The American Journal of Respiratory and Critical Care Medicine (AJRCCM) is planning a special issue to be distributed at the ATS 2019 International Conference, May 17–22, in Dallas, Texas.
The AJRCCM (impact factor: 15.24) welcomes submissions from our global respiratory community on respiratory medicine, critical care, and sleep disorders. While all original research will be considered, the editors are particularly seeking interventional clinical trials, as well as observational and translational studies, including real-world studies in respiratory, critical care, and sleep medicine.
Requirements
- All submissions should conform to the AJRCCM's formatting requirements, as outlined in the Instructions for Contributors.
- Be sure to mention the ATS Conference special issue in your online submission cover letter.
If you have any questions, please contact Marc Bendian.
Submissions for the special edition will also be considered for acceptance and publication in regular issues of AJRCCM.
Deadline: Tuesday, Jan. 15, 2019
Disaster Guidance: 10 Tips for Staying Healthy During Wildfires
Within the past week, fierce winds in Southern and Northern California have exacerbated the current wildfires in California. As of this writing, three major fires (Woolsey, Hill and Northern California’s Camp) are burning in Ventura County, in northwest Coastal Los Angeles County and Butte County in Northern California respectively. The Camp fire is now the deadliest fire in CA history.
The ATS is thinking of all of those affected by the fires, and the California Thoracic Society, a chapter of the ATS, has prepared an educational document to be shared with the general public, health care professionals and patients affected by the catastrophe of wildfires.
ATS Opposes FDA Decision to Approve Over-the-Counter Epinephrine for the Treatment of Asthma
The American Thoracic Society is gravely concerned and disappointed in the FDA’s decision to approve over-the-counter epinephrine (Primatene Mist HFA) for consumer use to treat asthma.
FDA’s decision contradicts existing and established clinical practice guidelines. Several expert panels have produced evidence-based recommendations on the treatment of patients with asthma. None of these guidelines recommend the use of inhaled epinephrine. By approving an over-the-counter epinephrine product to treat asthma, the FDA is endorsing a contra-indicated treatment for asthma.
FDA’s decision will jeopardize patient safety. Asthma is a serious respiratory condition and even patients with mild or intermittent asthma can experience life-threatening asthma exacerbations. This decision will give patients the false impression that over-the-counter epinephrine can manage their conditions.
FDA’s decision undermines our trust in a public policy process. It appears that the FDA reached its decision without seeking any input from the patient and provider community.
MITT Committee Twitter Chat
The Committee for Members in Transition and Training is hosting a "Careers in Medical Education" Twitter Chat tomorrow at 8 p.m. EST. The discussion will include available resources for medical educators-in-training, as well as ways to gain additional teaching skills and experience.
When: 8 p.m. EST, Thursday Nov. 15, 2018
Where: Twitter, using the hashtag #ATSchat.
Congratulations to 2019 ATS Fellows!
The ATS is excited to announce the 2019 ATS Fellows!
The ATS Fellow designation is a mark of distinction in recognition of the accomplishments, dedication, and contributions members have made to the Society, as well as to the fields of pulmonary, critical care, and sleep medicine.
ATS Fellows will also be recognized on the ATS website, and at the ATS 2019 International Conference.
